Waleed H. Hassanein Sells 7,500 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

Posted by Defense World Staff on Mar 4th, 2023

TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating) CEO Waleed H. Hassanein sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $80.72, for a total transaction of $605,400.00. Following the transaction, the chief executive officer now directly owns 381,117 shares of the company’s stock, valued at $30,763,764.24. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $82.33 on Friday. The firm has a market cap of $2.65 billion, a PE ratio of -65.86 and a beta of 1.47. The firm has a fifty day moving average of $65.26 and a 200 day moving average of $56.12. The company has a debt-to-equity ratio of 0.31, a quick ratio of 11.21 and a current ratio of 10.66. TransMedics Group, Inc. has a one year low of $16.16 and a one year high of $82.53.

TransMedics Group (NASDAQ:TMDX – Get Rating) last issued its quarterly earnings results on Wednesday, February 22nd. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.07. The company had revenue of $31.38 million during the quarter, compared to analyst estimates of $23.60 million. TransMedics Group had a negative net margin of 38.77% and a negative return on equity of 29.82%. The firm’s revenue was up 224.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.46) EPS. As a group, research analysts predict that TransMedics Group, Inc. will post -0.89 EPS for the current fiscal year.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Voya Investment Management LLC increased its holdings in TransMedics Group by 164.9% in the 4th quarter. Voya Investment Management LLC now owns 30,757 shares of the company’s stock worth $1,898,000 after acquiring an additional 19,148 shares in the last quarter. Natixis boosted its stake in TransMedics Group by 93.0% during the 4th quarter. Natixis now owns 71,388 shares of the company’s stock worth $4,406,000 after purchasing an additional 34,392 shares during the last quarter. Macquarie Group Ltd. boosted its stake in TransMedics Group by 11.3% during the 4th quarter. Macquarie Group Ltd. now owns 1,947,472 shares of the company’s stock worth $120,198,000 after purchasing an additional 197,273 shares during the last quarter. Alliancebernstein L.P. boosted its stake in TransMedics Group by 51.0% during the 4th quarter. Alliancebernstein L.P. now owns 31,700 shares of the company’s stock worth $1,957,000 after purchasing an additional 10,700 shares during the last quarter. Finally, Financial Advocates Investment Management boosted its stake in TransMedics Group by 50.3% during the 4th quarter. Financial Advocates Investment Management now owns 19,363 shares of the company’s stock worth $1,195,000 after purchasing an additional 6,481 shares during the last quarter. Hedge funds and other institutional investors own 88.58% of the company’s stock.

Analyst Ratings Changes

TMDX has been the subject of a number of recent research reports. Oppenheimer raised their price target on shares of TransMedics Group from $55.00 to $85.00 and gave the stock an “outperform” rating in a research report on Thursday, February 23rd. JPMorgan Chase & Co. raised their price target on shares of TransMedics Group from $67.00 to $81.00 and gave the stock an “overweight” rating in a research report on Thursday, February 23rd. Canaccord Genuity Group raised their price target on shares of TransMedics Group from $58.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, November 4th. Cowen lifted their target price on shares of TransMedics Group from $70.00 to $75.00 and gave the company an “outperform” rating in a report on Thursday, February 23rd. Finally, Morgan Stanley lifted their target price on shares of TransMedics Group from $63.00 to $74.00 and gave the company an “equal weight” rating in a report on Thursday, February 23rd. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, TransMedics Group presently has an average rating of “Moderate Buy” and a consensus target price of $71.57.

About TransMedics Group

(Get Rating)

TransMedics Group, Inc operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.